FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on atai Life Sciences N.V (ATAI)
-
-
-
-
-
-
-
AtaiBeckley receives FDA support for BPL-003 Phase 3 depression program
-
-
-
-
-
-
-
AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference
-
-
-
-
-
-
-
atai Life Sciences gets FDA breakthrough therapy status for depression drug
-
-
-
-
-
-
-
atai Life Sciences N.V (ATAI) PT Raised to $12 at Canaccord Genuity
-
-
-
-
-
-
-
Psychedelic stocks fall as FDA regulatory advisers fail to back MDMA-based PTSD treatment
-
-
-
-
-
-
-
atai Life Sciences (ATAI) Reports Positive Initial Results for Phase 1 Trial of KUR-101
-
324,764 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

